★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
Stock Profile
Pfizer Inc. (PFE) Moat Analysis
Pfizer Inc.
PFE · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
Pfizer is a global biopharmaceutical company with Biopharma as its sole reportable segment and Pfizer CentreOne as a smaller operating segment. The moat profile follows Pfizer's 2026 product groupings: Primary Care, Oncology, Specialty Care, and Hospital and Biosimilars. Patents and regulatory exclusivity are the only consistently evidenced barrier for the branded portfolios; they are time-bounded and do not prevent therapeutic competition. Hospital and Biosimilars and CentreOne operate in competitive, multisource markets without a separately supported moat. H1 2026 revenue rose 4% to $29.484B, or 6% operationally excluding Comirnaty and Paxlovid, while Pfizer expects about $1.1B of 2026 revenue pressure from exclusivity expiries. Pfizer reported 5,699,673,589 shares outstanding at July 29, 2026.
Primary segment
Primary Care
Market structure
Oligopoly
Market share
—
HHI: —
Coverage
5 segments · 7 tags
Updated 2026-08-09
Segments
Primary Care
Branded primary care medicines and vaccines (incl. cardiovascular, migraine, pneumococcal/RSV/COVID-19)
Revenue
37.5%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Specialty Care
Specialty medicines (inflammation and immunology, rare disease, and related specialty therapies)
Revenue
21.3%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Oncology
Innovative oncology therapeutics
Revenue
27.1%
Structure
Competitive
Pricing
moderate
Share
—
Peers
Hospital and Biosimilars
Off-patent branded medicines, sterile injectables, and biosimilars
Revenue
11.9%
Structure
Competitive
Pricing
weak
Share
—
Peers
Pfizer CentreOne
Contract development and manufacturing (CDMO) services and specialty active pharmaceutical ingredients (APIs)
Revenue
2.2%
Structure
Competitive
Pricing
weak
Share
—
Peers
Moat Claims
Primary Care
Branded primary care medicines and vaccines (incl. cardiovascular, migraine, pneumococcal/RSV/COVID-19)
Revenue share uses H1 2026 Form 10-Q Note 13C 'Significant Revenues by Product': Primary Care $11.046B of $29.485B in rounded product-group totals. The five groups sum $1M above reported company revenue because of rounding. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/pfe-20260628.htm
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Primary Care economics rely on patent portfolios and (where applicable) regulatory exclusivity that delay generic entry for key brands (e.g., Eliquis, Prevnar, Nurtec, Abrysvo, Comirnaty, Paxlovid).
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Loss of exclusivity and generic/biosimilar entry
- Patent litigation outcomes shortening exclusivity
- Therapeutic substitution from new branded entrants
Leading indicators
- Upcoming basic patent expiration years for top products
- ANDA/biosimilar filings and litigation milestones
- Net price realization (gross-to-net) trend
Counterarguments
- Patents do not prevent within-class competition that can erode value before loss of exclusivity
- Payers can compress net pricing even during exclusivity via rebates and utilization management
Specialty Care
Specialty medicines (inflammation and immunology, rare disease, and related specialty therapies)
Revenue share uses H1 2026 Form 10-Q Note 13C 'Significant Revenues by Product': Specialty Care $6.292B of $29.485B in rounded product-group totals; off-patent injectables and biosimilars are classified in Hospital and Biosimilars. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/pfe-20260628.htm
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Specialty Care franchises (e.g., rare disease and immunology biologics/small molecules) depend on patents and regulatory exclusivity to protect pricing and volume from rapid generic/biosimilar entry.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Biosimilar competition and price erosion post-LOE
- Safety warnings or label restrictions reducing demand
- Payer step therapy and utilization management
Leading indicators
- Exclusivity timelines for top Specialty Care brands
- Biosimilar approvals and launches in key markets
- Hospital formulary wins/losses
Counterarguments
- Biologics/biosimilars can erode net pricing even before full LOE via contracting pressure
- Some hospital/anti-infective categories behave more like commodities with limited differentiation
Oncology
Innovative oncology therapeutics
Revenue share uses H1 2026 Form 10-Q Note 13C 'Significant Revenues by Product': Oncology $7.991B of $29.485B in rounded product-group totals; off-patent biosimilars are classified in Hospital and Biosimilars. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/pfe-20260628.htm
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Approved oncology assets are protected by patents/exclusivity, which support high gross margins until loss of exclusivity; however, patent cliffs and biosimilar competition can compress value over time.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Patent expiry and generic entry
- New mechanisms of action outcompeting older standards
- Biosimilar adoption for oncology biologics
Leading indicators
- Patent litigation and extension outcomes
- Competitor label expansions vs Pfizer indications
- Biosimilar penetration rates where relevant
Counterarguments
- Exclusivity does not stop within-class branded competition that can erode pricing
- Oncology treatment choice is evidence-driven; weak differentiation leads to rapid switching
Hospital and Biosimilars
Off-patent branded medicines, sterile injectables, and biosimilars
Revenue share uses H1 2026 Form 10-Q Note 13C 'Significant Revenues by Product': Hospital and Biosimilars $3.494B of $29.485B in rounded product-group totals. The portfolio was created in 2026 and prior periods were reclassified; no independently evidenced moat is assigned. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/pfe-20260628.htm
Pfizer CentreOne
Contract development and manufacturing (CDMO) services and specialty active pharmaceutical ingredients (APIs)
Revenue share uses H1 2026 Form 10-Q revenue of $662M of $29.485B in rounded product-group totals. Contract manufacturing, API supply, and manufacturing agreements establish the business model but do not by themselves demonstrate a durable moat; immaterial residual Pfizer Ignite revenue is included. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/pfe-20260628.htm
Evidence
We own or have co-promotion and/or license rights related to a number of patents covering pharmaceutical and other products
Supports the claim that patents are a primary barrier to entry for branded medicines and vaccines.
we now expect an unfavorable revenue impact from patent-based or regulatory exclusivity expiries of approximately $1.1 billion
The current-year expiry impact illustrates the time-bounded nature of exclusivity for major Primary Care franchises.
We may become subject to competition from biosimilars referencing our biologic products
Highlights the primary erosion mechanism once exclusivity ends.
Risks & Indicators
Erosion risks
- Loss of exclusivity and generic/biosimilar entry
- Patent litigation outcomes shortening exclusivity
- Therapeutic substitution from new branded entrants
- Government price negotiation/price controls
- Biosimilar competition and price erosion post-LOE
- Safety warnings or label restrictions reducing demand
Leading indicators
- Upcoming basic patent expiration years for top products
- ANDA/biosimilar filings and litigation milestones
- Net price realization (gross-to-net) trend
- Share shifts to therapeutic alternatives
- Exclusivity timelines for top Specialty Care brands
- Biosimilar approvals and launches in key markets
Research PFE elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.